


**IN THE CLAIMS:**

**This listing of claims will replace all prior versions and listing of claims in the application.**


**Listing of claims:**

Claim 1 (**currently amended**): A compound of the formula (IA), (IB), (IC), (ID), (IE) and (IF) of the generic structure of formula (I):

**(I)**

wherein:

i) a compound of formula (IA) is selected from:

**(IA)**

wherein:

$R^1$  is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(thiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,2-dimethylpropyl, 1-methylcyclopropyl, 2,2-dimethylaziridin-1-yl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl, 2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl, 1-methoxyprop-2-yl,


1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or

2-methoxy-1,1-dimethylethyl; and

$R^2$  is hydrogen;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

ii) a compound of formula (IB) is selected from:



(IB)

wherein:


$R^1$  is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol-4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl, 2-pyridazin-4-ylethyl, 1,1-dimethylpropyn-2-yl or 2-ethoxyethyl; and

$R^2$  is hydrogen or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when  $R^1$  is 2-methoxyethyl,  $R^2$  is cyano;

iii) a compound of formula (IC) is selected from:



(IC)

wherein:


**R<sup>1</sup>** is hydrogen, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl;

**R<sup>2</sup>** is hydrogen, halo or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when R<sup>1</sup> is 2-methoxyethyl, R<sup>2</sup> is not hydrogen;

iv) a compound of formula (ID) is selected from:



(ID)


wherein:

**R<sup>1</sup>** is hydrogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkylC<sub>1-3</sub>alkyl, a heterocyclyl or heterocyclylC<sub>1-3</sub>alkyl; wherein R<sup>1</sup> may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

**R<sup>2</sup>** is hydrogen, halo or cyano;

**R<sup>3</sup>** is C<sub>2-6</sub>alkyl;

- or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;  
 v) a compound of formula **(IE)** is selected from:

**(IE)**

wherein:

**R<sup>1</sup>** is hydrogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkylC<sub>1-3</sub>alkyl, a heterocyclyl or heterocyclylC<sub>1-3</sub>alkyl; wherein R<sup>1</sup> may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

**R<sup>2</sup>** is halo, cyano, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxy;

**p** is 1-2; wherein the values of R<sup>2</sup> may be the same or different;


**R<sup>3</sup>** is hydrogen, halo or cyano;

**R<sup>4</sup>** is C<sub>1-4</sub>alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;  
 provided that said compound is not

4-(1,2-dimethylimidazol-5-yl)-2-[2-methoxy-4-(*N*-methylsulphamoyl)-5-methylanilino]  
 pyrimidine;

- vi) a compound of formula **(IF)** is selected from:



(IF)

wherein:

$R^1$  is  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{3-6}$ cycloalkyl,  $C_{3-6}$ cycloalkyl $C_{1-3}$ alkyl, a heterocyclyl or heterocyclyl $C_{1-3}$ alkyl; wherein  $R^1$  may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

$R^2$  is halo, cyano,  $C_{1-3}$ alkyl or  $C_{1-3}$ alkoxy;

$p$  is 0-2; wherein the values of  $R^2$  may be the same or different;

$R^3$  is hydrogen, halo or cyano;

$R^4$  is  $C_{2-6}$ alkyl;

$R^5$  is  $C_{1-6}$ alkyl or  $C_{2-6}$ alkenyl; wherein  $R^5$  may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an ~~*in vivo* hydrolysable ester~~ thereof.

Claim 2 (**previously presented**): The compound of formula (I) according to claim 1 which is a compound of formula (IA), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 (**currently amended**): The compound of formula (IA) according to claim 2 selected from:

2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;  
2-{4-[N-(*t*-butyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;  
2-{4-[N-(1-ethoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;  
2-{4-[N-(1-propoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;  
and  
2-{4-[N-(1-methylcyclopropyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 4 (**currently amended**): The compound of formula (I) according to claim 1 which is a compound of formula (IB), or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 5 (**currently amended**): The compound of formula (IB) according to claim 4 selected from:

4-(1-ethyl-2-methylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;  
and  
2-{4-[N-(1,1-dimethylprop-2-ynyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 6 (**currently amended**): The compound of formula (I) according to claim 1 which is a compound of formula (IC), or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 7 (**currently amended**): The compound of formula (IC) according to claim 6, or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof; wherein

R<sup>1</sup> is hydrogen, 2-methoxyethyl, methyl or 2-ethoxyethyl; and

R<sup>2</sup> is hydrogen or bromo;

provided that when R<sup>1</sup> is 2-methoxyethyl R<sup>2</sup> is not hydrogen.

Claim 8 (**currently amended**): The compound of formula (IC) according to claim 6 selected from:

4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine; and

4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino} pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 9 (**currently amended**): The compound of formula (I) according to claim 1 which is a compound of formula (ID), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 10 (**currently amended**): The compound of formula (ID) according to claim 9, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R<sup>1</sup> is cyclopropyl, 2-methoxyethyl or tetrahydrofur-2-ylmethyl;

R<sup>2</sup> is hydrogen; and

R<sup>3</sup> is ethyl or isopropyl.

Claim 11 (**currently amended**): The compound of formula (ID) according to claim 9 selected from:

4-(1-isopropylimidazol-5-yl)-2-{4-[N-(cyclopropyl)sulphamoyl]anilino} pyrimidine;

4-(1-isopropylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino} pyrimidine;

4-(1-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino} pyrimidine; and

4-(1-isopropylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino} pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 12 (**currently amended**): The compound of formula (**I**) according to claim 1 which is a compound of formula (**IE**), or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 13 (**currently amended**): The compound of formula (**IE**) according to claim 12, or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof; wherein  
R<sup>1</sup> is hydrogen or 2-methoxyethyl;  
R<sup>2</sup> is fluoro;  
p is 1;  
R<sup>3</sup> is hydrogen; and  
R<sup>4</sup> is methyl.

Claim 14 (**currently amended**): The compound of formula (**IE**) according to claim 12 selected from:

2-{4-[N-(2-methoxyethyl)sulphamoyl]-2-fluoroanilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and  
2-(4-sulphamoyl-2-fluoroanilino)-4-(1,2-dimethylimidazol-5-yl)pyrimidine;  
or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 15 (**currently amended**): The compound of formula (**I**) according to claim 1 which is a compound of formula (**IF**), or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 16 (**currently amended**): The compound of formula (**IF**) according to claim 15, or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof; wherein  
R<sup>1</sup> is methyl, 3-dimethylaminopropyl, 3-methoxypropyl, 3,3,3-trifluoropropyl or butyl;  
p is 0;  
R<sup>3</sup> is hydrogen;



R<sup>4</sup> is isopropyl; and

R<sup>5</sup> is methyl.

Claim 17 (**currently amended**): The compound of formula (**IF**) according to claim 15 selected from:

4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-mesylnilino)pyrimidine;

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-methoxypropylsulphonyl)anilino]pyrimidine;

and

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-*N,N*-dimethylaminopropylsulphonyl)anilino]pyrimidine;

or a pharmaceutically acceptable salt or an ~~*in vivo* hydrolysable ester~~ thereof.

Claims 18-20 (**cancelled**).

Claim 21 (**previously presented**): A pharmaceutical composition which comprises a compound of formula (**I**), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 22-34 (**cancelled**).

Claim 35 (**previously presented**): A method for treating rheumatoid arthritis in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (**I**) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claims 36-38 (**cancelled**).